Risks and Benefits of Phase I Liver Dysfunction Studies
Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.
Clinical Pearls
Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.
- There is not much known about the outcomes of patients on liver dysfunction trials.
- This analysis looked to evaluate clinical benefit rates, death on study rates, and rates of grade 3/4 toxicity for patients enrolled on 12 liver dysfunction phase I studies.
- Patients were classified by severity of liver dysfunction: mild, moderate, and severe.
- Patients in the ‘severe’ cohort experienced the lowest clinical benefit rates (5%) and highest rates of death (24%).
<<<
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
